Review anchor
Serine-threonine protein phosphatase 2A regulatory subunit
SINGLE PROTEIN · Gallus gallus
As of 2026-09-13
Evidence Snapshot
Serine-threonine protein phosphatase 2A regulatory subunit
CHEMBL2669
SINGLE PROTEIN
Gallus gallus
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Serine-threonine protein phosphatase 2A regulatory subunit as ChEMBL target CHEMBL2669, mapped to UniProt Q8AWE3. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL2669
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q8AWE3
Serine/threonine-protein phosphatase 2A 55 kDa regulatory subunit B
UniProt accession via ChEMBL component mapping
As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-13
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why Serine-threonine protein phosphatase 2A regulatory subunit matters
Serine-threonine protein phosphatase 2A regulatory subunit is reviewed as Serine/threonine-protein phosphatase 2A 55 kDa regulatory subunit B (UniProt Q8AWE3); the current evidence base includes 1 approved drug, 58 compounds, and 20 assays, with lead potency reaching pChEMBL 10.5.
Protein context
Serine/threonine-protein phosphatase 2A 55 kDa regulatory subunit B
Serine/threonine-protein phosphatase 2A 55 kDa regulatory subunit B Sequence length is 426 aa.
Review this target as Serine-threonine protein phosphatase 2A regulatory subunit, mapped to UniProt Q8AWE3. ChEMBL maps the protein component as Serine/threonine-protein phosphatase 2A 55 kDa regulatory subunit B. Sequence length is 426 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt Q8AWE3
Protein
Disease context
Disease signal
Disease relevance is not yet populated for this evidence card.
This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target recordActivity base
Portfolio and assay base
ChEMBL currently tracks 1 approved drug, 58 compounds, and 20 assays for this target. The dominant activity type is IC50. CHEMBL415297 is the current potency anchor at pChEMBL 10.5.
Use CHEMBL415297 as the tractability anchor when discussing potency (pChEMBL 10.5).
Activity source · ChEMBL 36 via Core Engine
1 approved
pChEMBL 10.5
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why Serine-threonine protein phosphatase 2A regulatory subunit matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q8AWE3, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
58
Total Compounds
20
Total Assays
1
Approved Drugs
IC50: 81.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL415297
|
10.5 | IC50 | — |
|
|
No preferred name
CHEMBL444092
|
10.0 | IC50 | — |
|
|
No preferred name
CHEMBL430266
|
9.7 | IC50 | — |
|
|
No preferred name
CHEMBL4524071
|
9.7 | IC50 | — |
|
|
No preferred name
CHEMBL17738
|
9.5 | IC50 | — |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
CANTHARIDIN
CHEMBL48449
|
2023 |
Source Header